BioSpace News Archive

Business

NeuBase Abandons Huntington’s, 60% of Workforce in Strategic Pivot

NeuBase announced a strategic restructuring, diverting resources from its Huntington’s program and shedding 60% of its workforce.

October 17, 2022
·
2 min read
·
Tristan Manalac
Business

Kineta, Merck Strike Deal to Pair Anti-VISTA Antibody with Keytruda

Kineta struck a collaboration deal with Merck to pair its anti-VISTA monoclonal antibody with Keytruda (pembrolizumab) as a potential treatment for advanced solid tumors.

October 17, 2022
·
2 min read
·
Alex Keown
Business

Biogen-Sage’s Zuranolone Impresses in Phase III Postpartum Depression Trial

Sage Therapeutics and Biogen’s zuranolone met its primary and key secondary endpoints in the Phase III SKYLARK study of women with postpartum depression (PPD).

October 17, 2022
·
2 min read
·
Tristan Manalac
Drug Development

In Latest Twist, FDA Delays Review of Biogen’s Tofersen by 3 Months

Biogen announced the FDA has extended its review for ALS drug tofersen by three months. The regulator set a new PDUFA action date set of April 25, 2023.

October 17, 2022
·
2 min read
·
Alex Keown
Business

Gilead, MacroGenics Unite Against Hematologic Cancers in $1.7B Biobuck Deal

Gilead Sciences and MacroGenics entered into a licensing and collaboration pact worth up to $1.7 billion to develop a bispecific antibody to treat hematological cancers.

October 17, 2022
·
2 min read
·
Mark Terry
Career Advice

Chemistry Job Options in the Life Sciences

Finding chemistry jobs in the life sciences industry doesn’t have to be difficult. Discover the top chemistry job options in the life sciences in our comprehensive guide.

October 17, 2022
·
4 min read
·
Kaley Lefevre
Drug Development

Milestone Gears Up to Submit Tachycardia Nasal Spray to Regulators

Milestone Pharmaceuticals reported highly positive data from its Phase III RAPID trial of etripamil in paroxysmal supraventricular tachycardia (PSVT) patients.

October 17, 2022
·
3 min read
·
Mark Terry
Policy

Minerva Shares Plunge After FDA Rejects Schizophrenia Drug Candidate

Shares of Massachusetts-based Minerva Neurosciences dropped Monday after the FDA issued a Refuse to File letter for the company’s schizophrenia drug, roluperidone.

October 17, 2022
·
2 min read
·
Mark Terry
Drug Development

Athira’s Late Stage Alzheimer’s Trial Advances Following Positive Interim Analysis

An analysis of un-blinded interim data showed fosgonimeton provided clinically meaningful improvements in cognition and function in patients with mild-to-moderate Alzheimer’s disease.

October 17, 2022
·
3 min read
·
Alex Keown
Bio NC

Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance

Verona Pharma plc, announces it has entered into a debt financing facility providing the Company with access to up to $150 million from Oxford Finance LLC.

October 17, 2022
·
7 min read